Zenas BioPharma Inc. (Ticker: ZBIO) is a clinical-stage biopharmaceutical company developing therapies for multiple sclerosis (MS) and autoimmune disorders. Incorporated in Delaware, the company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to treat several autoimmune diseases, including IgG4-related disease (IgG4-RD), MS, systemic lupus erythematosus (SLE), and warm autoimmune hemolytic anemia (wAIHA).

Zenas BioPharma will list on September 13, 2024, on NASDAQ. The firm is offering 11.8 million shares at a price range of $16.00 to $18.00 per share to raise approximately $199.9 million. The expected market capitalization at the time of the offer is $651.39 million. The offering is managed by Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities.